Gastrointestinale Stromatumoren – Aktuelle Therapieempfehlungen

Literatur

• 1 De Matteo R K, Owzar K R, Maki R. et al . Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I.  J Clin Oncol. 2007;  25 (18 Suppl) 10 079
• 2 Blanke C D, Demetri G D, von Mehren M. et al . Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.  J Clin Oncol. 2008;  26 620-625
• 3 Verweij J, Casali P G, Zalcberg J. et al . Progression-free survival in gastrointestinal stromal tumours with high-dose imatininb: randomized trial.  Lancet. 2004;  364 1127-1134
• 4 Blanke C D, Rankin C, Demetri G D. et al . Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033.  J Clin Oncol. 2008;  26 626-632
• 5 Zalcberg J R, Verveij J, Casali P G. et al . Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.  Eur J Cancer. 2005;  41 1751-1757
• 6 Blay J Y, Le Cesne A, Ray-Coquard I. et al . Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.  J Clin Oncol. 2007;  25 1107-1113
• 7 Demetri G D, van Oosterom A T, Garrett C R. et al . Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.  Lancet. 2006;  368 1329-1338